The use of fresh frozen plasma (FFP) has shown a dramatic increase in recent years. In the Welsh Region, covering a population of 2-2 million, 294 units were supplied in 1974, and this increased to over 5000 in 1983. Much of the growth in fresh plasma use has been for treatment or prevention of coagulation.disorders other than primary factor VIII deficiency or defibrination syndromes. In a recent local survey less than 5% of all FFP issued was required for conditions in which factor VIII values might be expected to be reduced. Most of the FFP was used during plasma exchange, massive transfusion, or cardiac surgery.
Previous examination of clotting, factor activity in cryosupernatant plasma has shown its potential value as a replacement fluid especially in large volume therapeutic plasma exchange and in severe factor V deficiency.'-3 Despite t-his evidence, FFP has continued to be the product of choice in a wide variety of conditions. It seemed worthwhile, therefore, to re-examine the potential value of fresh frozen cryosupernatant in place of FFP in circumstances such as fluid replacement for apheresis patients and prophylaxis of coagulation abnormalities occurring during massive transfusion.
Material and methods
Ten units of whole blood from healthy volunteer donors were collected into CPDA-1 triple bags (Travenol PL146). Within 6 h of donation the bloodwas centrifuged at 3500 g for 10 min at 4°C. The resultant platelet poor plasma was immediately expressed into a 300 ml satellite bag and each unit of concentrated red cells was sealed off. Aliquots of platelet poor plasma were snap frozen in liquid nitrogen for use as reference samples in coagulation Accepted for publication 4 December 1984 assays. The remainder was frozen for 2 h in metal containers in a blast freezer (Pritchard Laboratory Refrigeration) set at -60°C. The frozen platelet poor plasma was then thawed at 4°C for 12-16 h as for routine cryoprecipitate production. The cryoprecipitate was sedimented by centrifugation at 3500 g for 10 min at 4°C and the excess cryosupernatant was then siphoned into the second satellite bag. The cryoprecipitate, in about 15-20 ml plasma, was redissolved by placing it in a 37°C waterbath for 10 min; aliquots of this and the cryosupernatant were then snap frozen in liquid nitrogen. The volumes of plasma, cryoprecipitate, and cryosupernatant were calculated from their weights.
The coagulation factor content of platelet poor plasma, cryoprecipitate, and cryosupernatant were examined as outlined below:
The kaolin cephalin clotting test (KCCT), one stage prothrombin time, factor V assay, and one stage factor VIII assays were based on the methods described by Austen Coagulation Factor VIII Concentrate (human) was supplied by the National Institute for Biological Standards and Control, London. Fibrinogen concentrations were measured using a fibrinogen reagent kit (Boehringer Mannheim) and fibrinogen degradation products by a latex kit (MerciaBrocades Ltd). Fibronectin was assayed by immunoelectrophoresis using the Laurell rocket technique.5 In this technique, 187 ,ul of rabbit antihuman fibronectin was added to 25 ml of 1% agarose ME Seakem (Miles Laboratories). The electrophoresis buffer was 0-08 M Tris, 0-025 M Tricine buffer, pH 8-6.
Results
The percentages of factor V and factor VIII recovered in the cryosupernatant from the original plasma were 75% and 18*6% respectively (Table) .
The corresponding figures for fibrinogen and fibronectin were 64-6% and 45.3%.
Measurements of fibrinogen degradation products 475
Coagulation factor activities of 10 units ofplatelet poor plasma before and after processing into cryoprecipitate and cryosupernatant plasma mal. The concentration of fibrinogen degradation products is sufficiently low to be clinically insignificant. Frozen cryosupernatant could therefore be substituted for fresh frozen plasma for many of the clinical purposes for which the latter material is used. Cryoprecipitate, fresh blood, or plasma are best suited for management of the relatively uncommon defibrination syndrome and these products would also be preferred for broad spectrum haemostatic defects in neonates. Fresh frozen plasma should probably continue to be used for treatment of coagulation problems as a result of liver failure or the relatively uncommon congenital coagulation deficiency states for which specific concentrates are not available. Cryosupernatant seems well suited to use in place of fresh frozen plasma during plasma exchange and it has been used instead of albumin for this purpose without adverse effects.' There seems little reason why frozen cryosupernatant should not be substituted for fresh frozen plasma during major blood loss or cardiovascular surgery, especially when it is used to prevent the development of dilutional coagulation factor deficiencies. This wasteful practice of using fresh frozen plasma seems to have gained widespread acceptance even though it has been shown that clinically significant deficiencies are found relatively infrequently. 
